These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15065627)

  • 21. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 22. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical inquiries. Do TZDs increase the risk of heart failure for patients with diabetes?
    Baskin S; Neher JO; Dodson S; Hoffman R
    J Fam Pract; 2005 Aug; 54(8):723-4. PubMed ID: 16061064
    [No Abstract]   [Full Text] [Related]  

  • 24. Thiazolidinediones and fluid retention.
    Kiryluk K; Isom R
    Kidney Int; 2007 Sep; 72(6):762-8. PubMed ID: 17637710
    [No Abstract]   [Full Text] [Related]  

  • 25. Thiazolidinediones in heart failure: slippery when wet.
    Khush KK
    J Card Fail; 2008 Aug; 14(6):453-5. PubMed ID: 18672191
    [No Abstract]   [Full Text] [Related]  

  • 26. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.
    Erdmann E; Wilcox RG
    Eur Heart J; 2008 Jan; 29(1):12-20. PubMed ID: 18167366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.
    Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH; ;
    J Am Coll Cardiol; 2010 Apr; 55(17):1885-94. PubMed ID: 20413044
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
    Idris I; Warren G; Donnelly R
    Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosiglitazone and the thiazolidinediones: a changing context.
    Kenny C
    Prim Care Diabetes; 2007 Dec; 1(4):185-6. PubMed ID: 18632043
    [No Abstract]   [Full Text] [Related]  

  • 32. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pioglitazone-induced heart failure despite normal left ventricular function.
    Shah M; Kolandaivelu A; Fearon WF
    Am J Med; 2004 Dec; 117(12):973-4. PubMed ID: 15629744
    [No Abstract]   [Full Text] [Related]  

  • 34. The edematogenic properties of insulin.
    Kalambokis GN; Tsatsoulis AA; Tsianos EV
    Am J Kidney Dis; 2004 Oct; 44(4):575-90. PubMed ID: 15384008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thiazolidinedione associated volume overload and pulmonary hypertension.
    Michaelson J
    Ther Adv Cardiovasc Dis; 2008 Dec; 2(6):435-8. PubMed ID: 19124440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.
    Tang WH; Francis GS; Hoogwerf BJ; Young JB
    J Am Coll Cardiol; 2003 Apr; 41(8):1394-8. PubMed ID: 12706937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?
    García-Giménez JL; Sanchis-Gomar F; Pallardó FV
    Mov Disord; 2011 Apr; 26(5):769-71. PubMed ID: 21469214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rosiglitazone decision process at FDA and EMA. What should we learn?
    Pouwels KB; van Grootheest K
    Int J Risk Saf Med; 2012; 24(2):73-80. PubMed ID: 22751189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiazolinediones and heart failure: the potential to precipitate irreversible cardiac dysfunction.
    Iqbal MB; Fisher NG; Lyne JC; McDonagh TA
    Int J Cardiol; 2008 Jan; 123(2):e35-7. PubMed ID: 17320219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjudication of serious heart failure in patients from PROactive.
    Rydén L; Thráinsdóttir I; Swedberg K
    Lancet; 2007 Jan; 369(9557):189-90. PubMed ID: 17240282
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.